Biowise Limited - Limited company accounts 20.1

Biowise Limited - Limited company accounts 20.1


IRIS Accounts Production v22.1.4.3 04305295 Board of Directors 1.1.21 31.12.21 31.12.21 waste recycling. true true false true true true false false false true true true false Ordinary 1.00000 Ordinary A 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure043052952020-12-31043052952021-12-31043052952021-01-012021-12-31043052952019-12-31043052952020-01-012020-12-31043052952020-12-3104305295ns16:EnglandWales2021-01-012021-12-3104305295ns15:PoundSterling2021-01-012021-12-3104305295ns11:Director12021-01-012021-12-3104305295ns11:PrivateLimitedCompanyLtd2021-01-012021-12-3104305295ns11:FRS1022021-01-012021-12-3104305295ns11:Audited2021-01-012021-12-3104305295ns11:LargeMedium-sizedCompaniesRegimeForDirectorsReport2021-01-012021-12-3104305295ns11:LargeMedium-sizedCompaniesRegimeForAccounts2021-01-012021-12-3104305295ns11:FullAccounts2021-01-012021-12-3104305295ns6:JointVenture12021-01-012021-12-310430529512021-01-012021-12-3104305295ns11:OrdinaryShareClass12021-01-012021-12-3104305295ns11:OrdinaryShareClass22021-01-012021-12-3104305295ns11:Director22021-01-012021-12-3104305295ns11:Director32021-01-012021-12-3104305295ns11:RegisteredOffice2021-01-012021-12-3104305295ns6:CurrentFinancialInstruments2021-12-3104305295ns6:CurrentFinancialInstruments2020-12-3104305295ns6:Non-currentFinancialInstruments2021-12-3104305295ns6:Non-currentFinancialInstruments2020-12-3104305295ns6:ShareCapital2021-12-3104305295ns6:ShareCapital2020-12-3104305295ns6:RevaluationReserve2021-12-3104305295ns6:RevaluationReserve2020-12-3104305295ns6:RetainedEarningsAccumulatedLosses2021-12-3104305295ns6:RetainedEarningsAccumulatedLosses2020-12-3104305295ns6:ShareCapital2019-12-3104305295ns6:RetainedEarningsAccumulatedLosses2019-12-3104305295ns6:RevaluationReserve2019-12-3104305295ns6:RetainedEarningsAccumulatedLosses2020-01-012020-12-3104305295ns6:RevaluationReserve2020-01-012020-12-3104305295ns6:RetainedEarningsAccumulatedLosses2021-01-012021-12-3104305295ns6:RevaluationReserve2021-01-012021-12-3104305295ns6:IntangibleAssetsOtherThanGoodwill2021-01-012021-12-3104305295ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-01-012021-12-3104305295ns6:OwnedOrFreeholdAssetsns6:LandBuildings2021-01-012021-12-3104305295ns6:ShortLeaseholdAssetsns6:LandBuildings2021-01-012021-12-3104305295ns6:PlantMachinery2021-01-012021-12-3104305295ns6:OwnedAssets2021-01-012021-12-3104305295ns6:OwnedAssets2020-01-012020-12-3104305295112021-01-012021-12-3104305295112020-01-012020-12-3104305295122021-01-012021-12-3104305295122020-01-012020-12-3104305295ns6:HirePurchaseContracts2021-01-012021-12-3104305295ns6:HirePurchaseContracts2020-01-012020-12-3104305295ns11:OrdinaryShareClass12020-01-012020-12-3104305295ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2020-12-3104305295ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-12-3104305295ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2020-12-3104305295ns6:LandBuildings2020-12-3104305295ns6:ShortLeaseholdAssetsns6:LandBuildings2020-12-3104305295ns6:PlantMachinery2020-12-3104305295ns6:LandBuildings2021-01-012021-12-3104305295ns6:LandBuildings2021-12-3104305295ns6:ShortLeaseholdAssetsns6:LandBuildings2021-12-3104305295ns6:PlantMachinery2021-12-3104305295ns6:LandBuildings2020-12-3104305295ns6:ShortLeaseholdAssetsns6:LandBuildings2020-12-3104305295ns6:PlantMachinery2020-12-3104305295ns6:CostValuation2020-12-3104305295ns6:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-12-3104305295ns6:CostValuation2021-12-3104305295ns6:Subsidiary12021-01-012021-12-31043052951ns6:Subsidiary12021-01-012021-12-3104305295ns6:Subsidiary12021-12-3104305295ns6:Subsidiary12020-12-3104305295ns6:Subsidiary12020-01-012020-12-3104305295ns6:Subsidiary22021-01-012021-12-3104305295ns6:Subsidiary232021-01-012021-12-3104305295ns6:Subsidiary22021-12-3104305295ns6:Subsidiary22020-12-3104305295ns6:Subsidiary32021-01-012021-12-31043052955ns6:Subsidiary32021-01-012021-12-3104305295ns6:Subsidiary32021-12-3104305295ns6:Subsidiary32020-12-3104305295ns6:JointVenture112021-01-012021-12-3104305295ns6:JointVenture12021-12-3104305295ns6:JointVenture12020-12-3104305295ns6:WithinOneYearns6:CurrentFinancialInstruments2021-12-3104305295ns6:WithinOneYearns6:CurrentFinancialInstruments2020-12-3104305295ns6:BetweenOneTwoYearsns6:Non-currentFinancialInstruments2021-12-3104305295ns6:BetweenOneTwoYearsns6:Non-currentFinancialInstruments2020-12-3104305295ns6:BetweenTwoFiveYearsns6:Non-currentFinancialInstruments2021-12-3104305295ns6:BetweenTwoFiveYearsns6:Non-currentFinancialInstruments2020-12-3104305295ns6:WithinOneYearns6:HirePurchaseContracts2021-12-3104305295ns6:WithinOneYearns6:HirePurchaseContracts2020-12-3104305295ns6:BetweenOneFiveYearsns6:HirePurchaseContracts2021-12-3104305295ns6:BetweenOneFiveYearsns6:HirePurchaseContracts2020-12-3104305295ns6:HirePurchaseContracts2021-12-3104305295ns6:HirePurchaseContracts2020-12-3104305295ns6:WithinOneYearns6:CurrentFinancialInstrumentsns6:HirePurchaseContracts2021-12-3104305295ns6:WithinOneYearns6:CurrentFinancialInstrumentsns6:HirePurchaseContracts2020-12-3104305295ns6:WithinOneYear2021-12-3104305295ns6:WithinOneYear2020-12-3104305295ns6:BetweenOneFiveYears2021-12-3104305295ns6:BetweenOneFiveYears2020-12-3104305295ns6:AllPeriods2021-12-3104305295ns6:AllPeriods2020-12-3104305295ns6:Secured2021-12-3104305295ns6:Secured2020-12-3104305295ns6:DeferredTaxation2020-12-3104305295ns6:DeferredTaxation2021-01-012021-12-3104305295ns6:DeferredTaxation2021-12-3104305295ns11:OrdinaryShareClass12021-12-3104305295ns11:OrdinaryShareClass22021-12-3104305295ns6:RetainedEarningsAccumulatedLosses2020-12-3104305295ns6:RevaluationReserve2020-12-31043052952ns11:Director22020-12-31043052952ns11:Director22019-12-31043052952ns11:Director22021-01-012021-12-31043052952ns11:Director22020-01-012020-12-31043052952ns11:Director22021-12-31043052952ns11:Director22020-12-3104305295ns6:OtherRelatedParties2021-01-012021-12-31
REGISTERED NUMBER: 04305295 (England and Wales)


















Biowise Limited

Strategic Report, Report of the Directors and

Financial Statements for the Year Ended 31st December 2021






Biowise Limited (Registered number: 04305295)






Contents of the Financial Statements
for the year ended 31st December 2021




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Income Statement 8

Other Comprehensive Income 9

Balance Sheet 10

Statement of Changes in Equity 11

Notes to the Financial Statements 12


Biowise Limited

Company Information
for the year ended 31st December 2021







DIRECTORS: J A C Landau
R M Wilkes
S J Wardell



REGISTERED OFFICE: Albion House
Albion Lane
Willerby
East Yorkshire
HU10 6TS



REGISTERED NUMBER: 04305295 (England and Wales)



AUDITORS: Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA



BANKERS: Virgin Bank Plc
10 Paragon Street
Hull
HU1 3ND

Biowise Limited (Registered number: 04305295)

Strategic Report
for the year ended 31st December 2021

The directors present their strategic report of the company for the year ended 31 December 2021. The directors are pleased with the company's performance and results for the year.

The principal activity of the group is treatment of residential organic waste serving long term Local Authority contracts through a combination of IVC, ASP and OWC composting technology.

REVIEW OF BUSINESS
The company has performed in line with forecast across all business activities.

PRINCIPAL RISKS AND UNCERTAINTIES
Like many businesses the most significant risk affecting the company are considered to be rising inflation, fuel and energy costs, all of which will present challenges to trading into 2022 and beyond.

FUTURE DEVELOPMENT AND PERFORMANCE
To maintain and improve profit levels over the short to medium term there will be a real focus on cost minimisation and improved efficiencies. This strategy will be complimented by ongoing carefully managed growth, striving to expand our client base in the north of England and regional areas beyond; especially where there are demonstrable synergies to existing skill-sets, facilities and profitability.

KEY PERFORMANCE INDICATORS
Week by week comparisons between previous year tonnage against the current year will be used to ensure the business stays on track. This enables time for intervention as required. Key cost drivers including fuel, electricity and offtakes will be monitored closely to ensure costs are kept to a minimum at no less than monthly intervals.

The current portfolio of KPI's will continue to be formulated and reviewed on a monthly basis.

As always safety, compliance and the environment form the keystone of any decision making.

ON BEHALF OF THE BOARD:





S J Wardell - Director


18th May 2022

Biowise Limited (Registered number: 04305295)

Report of the Directors
for the year ended 31st December 2021

The directors present their report with the financial statements of the company for the year ended 31st December 2021.

DIVIDENDS
The total distribution of dividends for the year ended 31st December 2021 will be £61,134.

DIRECTORS
The directors shown below have held office during the whole of the period from 1st January 2021 to the date of this report.

J A C Landau
R M Wilkes
S J Wardell

GOING CONCERN
The company has net assets of £6,008,290 at 31 December 2021; made a profit before tax of £2,166,444 in the year; and is highly cash generative. Financial forecasts for the next two financial years show similar profitability and cash generation going forward and demonstrate the company's ability to service its debts and manage working capital with significant headroom. The directors are therefore satisfied that the financial statements should be prepared on a going concern basis.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Biowise Limited (Registered number: 04305295)

Report of the Directors
for the year ended 31st December 2021


AUDITORS
The auditors, Smailes Goldie, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





S J Wardell - Director


18th May 2022

Report of the Independent Auditors to the Members of
Biowise Limited

Opinion
We have audited the financial statements of Biowise Limited (the 'company') for the year ended 31st December 2021 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31st December 2021 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Matter
The corresponding figures relating to the prior period were not audited.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report of the Independent Auditors to the Members of
Biowise Limited


Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, anti-bribery, Environment Agency legislation, and health and safety legislation. An understanding of these laws and regulations and the extent of compliance was obtained through discussion with management and inspecting legal and regulatory correspondence.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by making enquiries of management and considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates were
indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

Report of the Independent Auditors to the Members of
Biowise Limited

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with relevant regulators and the limited liability partnership's legal advisors.

Due to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission, or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Stephen Bramall BSc FCA (Senior Statutory Auditor)
for and on behalf of Smailes Goldie
Chartered Accountants
Statutory Auditor
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

18th May 2022

Biowise Limited (Registered number: 04305295)

Income Statement
for the year ended 31st December 2021

2021 2020
Notes £    £    £    £   

TURNOVER 13,347,161 11,050,797

Cost of sales 8,956,532 7,024,086
GROSS PROFIT 4,390,629 4,026,711

Administrative expenses - impairment
charges

565,096

-
Administrative expenses - others 1,455,583 1,437,209
2,020,679 1,437,209
2,369,950 2,589,502

Other operating income 23,667 55,085
OPERATING PROFIT 4 2,393,617 2,644,587

Interest receivable and similar income 797 4,736
2,394,414 2,649,323

Interest payable and similar expenses 5 227,970 260,415
PROFIT BEFORE TAXATION 2,166,444 2,388,908

Tax on profit 6 758,616 430,686
PROFIT FOR THE FINANCIAL YEAR 1,407,828 1,958,222

Biowise Limited (Registered number: 04305295)

Other Comprehensive Income
for the year ended 31st December 2021

2021 2020
Notes £    £   

PROFIT FOR THE YEAR 1,407,828 1,958,222


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

1,407,828

1,958,222

Biowise Limited (Registered number: 04305295)

Balance Sheet
31st December 2021

2021 2020
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 8 - -
Tangible assets 9 8,292,534 8,496,266
Investments 10 - 355,000
8,292,534 8,851,266

CURRENT ASSETS
Debtors 11 4,000,919 1,745,791
Cash at bank 420,199 2,224,133
4,421,118 3,969,924
CREDITORS
Amounts falling due within one year 12 2,651,438 2,834,710
NET CURRENT ASSETS 1,769,680 1,135,214
TOTAL ASSETS LESS CURRENT
LIABILITIES

10,062,214

9,986,480

CREDITORS
Amounts falling due after more than one
year

13

(3,011,909

)

(4,530,024

)

PROVISIONS FOR LIABILITIES 17 (1,042,015 ) (771,193 )

ACCRUALS AND DEFERRED INCOME 18 - (23,667 )
NET ASSETS 6,008,290 4,661,596

CAPITAL AND RESERVES
Called up share capital 19 130 130
Revaluation reserve 20 720,385 720,385
Retained earnings 20 5,287,775 3,941,081
SHAREHOLDERS' FUNDS 6,008,290 4,661,596

The financial statements were approved by the Board of Directors and authorised for issue on 18th May 2022 and were signed on its behalf by:





S J Wardell - Director


Biowise Limited (Registered number: 04305295)

Statement of Changes in Equity
for the year ended 31st December 2021

Called up
share Retained Revaluation Total
capital earnings reserve equity
£    £    £    £   

Balance at 1st January 2020 130 2,554,253 720,385 3,274,768

Changes in equity
Dividends - (571,394 ) - (571,394 )
Total comprehensive income - 1,958,222 - 1,958,222
Balance at 31st December 2020 130 3,941,081 720,385 4,661,596

Changes in equity
Dividends - (61,134 ) - (61,134 )
Total comprehensive income - 1,407,828 - 1,407,828
Balance at 31st December 2021 130 5,287,775 720,385 6,008,290

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements
for the year ended 31st December 2021

1. STATUTORY INFORMATION

Biowise Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements continue to be prepared on a going concern basis.

The significant accounting polices applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Going concern
The company has net assets of £6,008,290 at 31 December 2021; made a profit before tax of £2,166,444 in the year; and is highly cash generative. Financial forecasts for the next two financial years show similar profitability and cash generation going forward and demonstrate the company's ability to service its debts and manage working capital with significant headroom. The directors are therefore satisfied that the financial statements should be prepared on a going concern basis.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows;
the requirement of paragraph 3.17(d);
the requirement of paragraph 33.7.

Preparation of consolidated financial statements
The financial statements contain information about Biowise Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable net of VAT and trade discounts. The policies adopted for the recognition of turnover are as follows:

When the outcome of a transaction can be estimated reliably, turnover from the provision of waste management services is recognised when the service has been provided.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Other intangibles are being amortised evenly over their estimated useful life of five years.

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost
Short leasehold - Over lease term
Plant and machinery - 10% - 25% on cost

The company has taken the exemption conferred in section 35.10(c) of FRS 102 and used the fair value of freehold land at the date of transition as its deemed cost.

Investments in subsidiaries
Investments in subsidiaries are stated at cost less provision for impairment.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Hire purchase and leasing commitments
Assets obtained under hire purchase contracts are capitalised as tangible assets and depreciated over their useful lives. Obligations under such agreements are included in creditors net of finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

Share based payments
The cost of equity-settled transactions with employees is measured by reference to their fair value of the financial instrument granted at the date at which they are granted and is recognised as an expense over the vesting period, which starts once the vesting conditions have been met and ends once the relevant employee becomes fully entitled to the award.

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

3. EMPLOYEES AND DIRECTORS
2021 2020
£    £   
Wages and salaries 1,331,125 1,032,848
Social security costs 131,086 101,035
Other pension costs 104,633 92,126
1,566,844 1,226,009

The average number of employees during the year was as follows:
2021 2020

Direct labour 43 39

2021 2020
£    £   
Directors' remuneration 137,549 137,512

4. OPERATING PROFIT

The operating profit is stated after charging:

2021 2020
£    £   
Other operating leases 34,091 33,227
Depreciation - owned assets 656,915 717,671
Loss on disposal of fixed assets 18,941 37,080
Foreign exchange differences - 28
Impairment charge against investment in subsidiary (see note 10) 355,000 -
Impairment charge against group loan 210,096 -

5. INTEREST PAYABLE AND SIMILAR EXPENSES
2021 2020
£    £   
Bank interest 1,662 609
Bank loan interest 67,767 77,809
Hire purchase 158,541 181,997
227,970 260,415

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

6. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2021 2020
£    £   
Current tax:
UK corporation tax 481,891 335,438
Corporation tax under-provided in previous
years

5,903

-
Total current tax 487,794 335,438

Deferred tax:
Origination and reversal of timing differences 48,414 125,313
Effect of changes in tax rates 222,408 -
Over-provided previously - (30,065 )
Total deferred tax 270,822 95,248

Tax on profit 758,616 430,686

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2021 2020
£    £   
Profit before tax 2,166,444 2,388,908
Profit multiplied by the standard rate of corporation tax in the UK of
19% (2020 - 19%)

411,624

453,893

Effects of:
Expenses not deductible for tax purposes 12,512 20,567
Adjustments to tax charge in respect of previous periods 5,903 (30,065 )
Change in tax rates on opening deferred tax provision 222,408 -
Impairment of assets not tax deductible 107,368 -
Capital allowances super deduction (1,199 ) -
Group relief - (13,709 )
Total tax charge 758,616 430,686

UK corporation tax has been charged at 19% (2020: 19%).

In the Spring Budget 2021, the Government announced that from 1st April 2023 the corporation tax rate will increase to 25%. The deferred tax provision has been based on the rates applicable to the years in which the timing differences reverse.

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

7. DIVIDENDS
2021 2020
£    £   
Ordinary shares of £1 each
Interim 61,134 571,394

8. INTANGIBLE FIXED ASSETS
Other
intangibles
£   
COST
At 1st January 2021
and 31st December 2021 65,533
AMORTISATION
At 1st January 2021
and 31st December 2021 65,533
NET BOOK VALUE
At 31st December 2021 -
At 31st December 2020 -

9. TANGIBLE FIXED ASSETS
Freehold Short Plant and
property leasehold machinery Totals
£    £    £    £   
COST
At 1st January 2021 4,885,509 1,044,905 4,835,429 10,765,843
Additions 14,447 - 479,934 494,381
Disposals - - (169,770 ) (169,770 )
At 31st December 2021 4,899,956 1,044,905 5,145,593 11,090,454
DEPRECIATION
At 1st January 2021 445,245 69,660 1,754,672 2,269,577
Charge for year 81,526 69,660 505,729 656,915
Eliminated on disposal - - (128,572 ) (128,572 )
At 31st December 2021 526,771 139,320 2,131,829 2,797,920
NET BOOK VALUE
At 31st December 2021 4,373,185 905,585 3,013,764 8,292,534
At 31st December 2020 4,440,264 975,245 3,080,757 8,496,266

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

10. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1st January 2021 355,000
Impairments (355,000 )
At 31st December 2021 -
NET BOOK VALUE
At 31st December 2021 -
At 31st December 2020 355,000

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Dispit Limited
Registered office: Albion House, Albion Lane, Willerby, East Yorkshire, HU10 6TS.
Nature of business: Landfill
%
Class of shares: holding
Ordinary 100.00
2021 2020
£    £   
Aggregate capital and reserves (211,659 ) 314,908
Loss for the year (526,567 ) (40,036 )

Wastewise (UK) Limited
Registered office: Albion House, Albion Lane, Willerby, East Yorkshire, HU10 6TS.
Nature of business: Dormant
%
Class of shares: holding
Ordinary 100.00
2021 2020
£    £   
Aggregate capital and reserves 100 100

Wastewise Limited
Registered office: Albion House, Albion Lane, Willerby, East Yorkshire, HU10 6TS.
Nature of business: Dormant
%
Class of shares: holding
Ordinary 100.00
2021 2020
£    £   
Aggregate capital and reserves 100 100

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

10. FIXED ASSET INVESTMENTS - continued

Joint venture

J & B Bio Limited
Registered office: Windermere MRF, Thomlinson Road, Hartlepool, TS25 1NS
Nature of business: Waste management
%
Class of shares: holding
Ordinary 50.00
31.3.21 31.3.20
£    £   
Aggregate capital and reserves 100 100

11. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Trade debtors 1,565,577 1,257,260
Amounts owed by group undertakings 149,769 244,709
Other debtors 1,744 2,600
Directors and shareholders' loans 2,000,581 -
Prepayments 283,248 241,222
4,000,919 1,745,791

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2021 2020
£    £   
Bank loans and overdrafts (see note 14) 279,789 246,709
Other loans (see note 14) 5,081 50,081
Hire purchase contracts (see note 15) 669,278 674,147
Trade creditors 874,726 1,064,339
Corporation tax 481,891 335,438
Social security and other taxes 62,754 210,898
Other creditors 16,047 14,535
Accruals and deferred income 261,872 238,563
2,651,438 2,834,710

13. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2021 2020
£    £   
Bank loans (see note 14) 1,849,602 2,148,610
Hire purchase contracts (see note 15) 1,162,307 1,538,395
Shareholders' loans - 843,019
3,011,909 4,530,024

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

14. LOANS

An analysis of the maturity of loans is given below:

2021 2020
£    £   
Amounts falling due within one year or on demand:
Bank loans 279,789 246,709
Loans from related party companies 5,081 50,081
284,870 296,790

Amounts falling due between one and two years:
Bank loans 269,455 279,789

Amounts falling due between two and five years:
Bank loans 696,728 750,025

Amounts falling due in more than five years:

Repayable by instalments
Bank loans 883,419 1,118,796

15. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
2021 2020
£    £   
Gross obligations repayable:
Within one year 826,418 829,203
Between one and five years 1,375,178 1,868,601
2,201,596 2,697,804

Finance charges repayable:
Within one year 157,140 155,056
Between one and five years 212,871 330,206
370,011 485,262

Net obligations repayable:
Within one year 669,278 674,147
Between one and five years 1,162,307 1,538,395
1,831,585 2,212,542

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

15. LEASING AGREEMENTS - continued

Non-cancellable operating leases
2021 2020
£    £   
Within one year 33,019 57,063
Between one and five years 11,006 44,025
44,025 101,088

16. SECURED DEBTS

The following secured debts are included within creditors:

2021 2020
£    £   
Bank loans 2,129,391 2,395,319
Hire purchase contracts 1,831,585 2,212,542
Shareholder loans - 843,019
3,960,976 5,450,880

The above debts are all secured by fixed and floating charges on all of the assets of the company.

17. PROVISIONS FOR LIABILITIES
2021 2020
£    £   
Deferred tax
Accelerated capital allowances 1,042,015 771,193

Deferred
tax
£   
Balance at 1st January 2021 771,193
Charge to Income Statement during year 270,822
Balance at 31st December 2021 1,042,015

The expected net reversal of the deferred tax provision in 2022 is £91,320.

18. ACCRUALS AND DEFERRED INCOME

Accruals and deferred income represents deferred capital grants.

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

19. CALLED UP SHARE CAPITAL



Allotted, issued and fully paid:
Number: Class: Nominal 2021 2020
value: £    £   
120 Ordinary £1 120 120
10 Ordinary A £1 10 10
130 130

20. RESERVES
Retained Revaluation
earnings reserve Totals
£    £    £   

At 1st January 2021 3,941,081 720,385 4,661,466
Profit for the year 1,407,828 - 1,407,828
Dividends (61,134 ) - (61,134 )
At 31st December 2021 5,287,775 720,385 6,008,160

21. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31st December 2021 and 31st December 2020:

2021 2020
£    £   
J A C Landau
Balance outstanding at start of year - -
Amounts advanced 2,995,581 -
Amounts repaid (995,000 ) -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 2,000,581 -

Loans made to the directors are on an interest free basis.

22. RELATED PARTY DISCLOSURES

The company owed J A C Landau and close family £nil as at 31 December 2021 in respect of a loan account .(2020 - £843,019).

The above is a shareholder of Wastewise Holdings Limited, the parent company.

23. ULTIMATE CONTROLLING PARTY

The ultimate parent company is Wastewise Holdings Limited, a company registered in the United Kingdom. The registered office is Albion House, Albion Lane, Willerby, East Yorkshire, HU10 6TS. Wastewise Holdings Limited is the only company in which the company's results are consolidated.

J Landau is ultimate controlling party by virtue of his controlling stake in Wastewise Holdings Limited.

Biowise Limited (Registered number: 04305295)

Notes to the Financial Statements - continued
for the year ended 31st December 2021

24. SHARE-BASED PAYMENT TRANSACTIONS

Certain employees participate in the Wastewise Holdings Limited 2018 EMI Scheme Option Plan. Options were granted on 28 March 2018 and lapse if not exercised within ten years of that date. The vesting condition require a change in ultimate control of the company. The vesting condition has not yet been met, so no share based payments expense has been recognised through the income statement to date.

Options over 20 unissued ordinary shares of £1 each were outstanding at 31 December 2020 and 31 December 2021, with no options being capable of being exercised. No options were granted, forfeited, exercised or expired in the year.

The exercise price on each option is £15,833.33 per ordinary share of £1 each.